The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Interim Results

23 Oct 2017 07:00

RNS Number : 2507U
Omega Diagnostics Group PLC
23 October 2017
 

 

Omega Diagnostics Group PLC

("Omega" or "the Company")

 

Trading Update and Notice of Interim Results

 

Omega (AIM: ODX), the medical diagnostics company focused on allergy, food intolerance and infectious disease, announces the following trading update for the six months to 30 September 2017, in advance of releasing its interim results on Thursday 14 December 2017.

 

Financial update

 

Turnover is expected to be £7.11m, in line with last year's first half in constant currency terms and 4% ahead of last year's result (2016: £6.83m) on an actual basis. This reflects the weakening of sterling in the post-Brexit environment. Profit before tax (before share-based payments, IFRS-related discount unwinds and amortisation of intangible assets) is in line with expectation at the half-year stage.

 

Segmental revenues are expected to be as follows:

 

 

Revenue to

30 September 2017

Revenue to

30 September 2016

 

% increase

% increase CER*

Food Intolerance

£4.13m

£3.84m

+ 8%

+ 4%

Allergy/Autoimmune

£1.67m

£1.76m

- 5%

- 11%

Infectious Disease/Other

£1.31m

£1.23m

+ 7%

+ 5%

TOTAL

£7.11m

£6.83m

+ 4%

+ 1%

 

* Constant exchange rate ("CER") numbers have been restated to remove the impact of foreign exchange movements in the year by restating the performance for the six months ended 30 September 2017 using the exchange rates during the prior period.

Core business update

 

Food Intolerance

We continue to see strong growth in North America with our microarray-based FoodPrint® test. As noted below, North America is a priority market for us and we are focusing resource more closely into this market. With regard to the self-test version of Food Detective®, the Company was able to successfully complete the actions requested of it by Lloyds Register Quality Assurance ("LRQA") within the agreed timescale and we are awaiting LRQA's final review outcome.

 

Allergy/Autoimmune

Revenue in the first half of the current financial year declined by 8.5% in our German domestic business, compared to the previous period. A significant amount of above-average rainfall in July was a contributing factor but we are expecting a better performance in the second half of the year. The reduction in euro-denominated revenue was mitigated by the weakening in the pound/euro exchange rate compared to last year.

 

Infectious Disease

This segment has started to benefit from initial sales of the VISITECT® range of Malaria tests manufactured at the facility in Pune, India. A small percentage increase in revenue in actual terms has been positively impacted by the weaker position of sterling, as noted above.

 

 Accelerated growth strategy

 

As announced in July, the Company was successful in raising funds from two sources:

 

· £3.3 million (before expenses) from a placing and open offer

· €0.8 million (before rent deposit) from the sale and leaseback of its German manufacturing facility

 

These funds were raised to enable the Company to exploit opportunities which it has identified to accelerate growth.

 

Increase FoodPrint® traction in the USA

As reported on 16 October 2017, the Company has signed a supply agreement with a new partner in the US, bringing the number of partners that the Company is currently working with in the US to three. We continue to believe that the US market represents a key driver for growth in what is the world's largest market for food sensitivity testing.

 

Allersys® product range

We remain on plan to increase the number of CE-Marked allergens that have been developed for use on the IDS instrument to 50-60 allergens by the end of the current financial year. We have had two positive meetings recently with Immunodiagnostics Systems ("IDS") and, subject to finalising a global distribution agreement, we are now confident that we can commercialise our range of products within the current financial year on terms which are beneficial to both parties.

 

Visitect® CD4

We have successfully manufactured bulk components for three validation batches of Visitect®CD4 which have passed QC testing at external sites and have now been assembled into devices. The first two batches of assembled devices have passed final QC testing with external testing. A third batch will begin external testing imminently. We have started using these validation batches to verify performance and this programme of testing is about 50% complete. External performance evaluations are underway at two UK hospital sites and we expect these to be completed within the next few weeks. The external performance evaluation in India is now complete and the data is being fully analysed with performance as expected on an initial review of the data. We therefore remain confident in our ability to CE-Mark the test before the end of the calendar year.

 

Outlook

 

We have made significant progress on a number of key objectives including:

 

· progress with validating and verifying the performance of Visitect® CD4

· increasing our presence in the North American market for food sensitivity testing

· progress with the commercialisation plan for our panel of Allersys® reagents

· increasing traction with Visitect® Malaria sales

 

Trading in the first half of the current financial year was in line with the comparative period in the prior year on a like-for-like basis. We expect a stronger second half and the outturn for the year remains dependent on one or more of the objectives outlined above delivering a material contribution to our results.

 

David Evans, Chairman of Omega commented: "We continue to advance as a Company in all our key areas and the outlook over the next twelve to eighteen months remains positive - the shorter term is dominated by factors not wholly within our control. We continue to be enthusiastic about prospects for Omega and we hope to announce further progress later in the year.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

Contacts:

 

Omega Diagnostics Group PLC

Tel: 01259 763 030

David Evans, Chairman

Andrew Shepherd, Chief Executive

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

 

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/James Thompson (Corporate Finance)

 

Mia Gardner (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCLLFFEISLIFID
Date   Source Headline
28th Nov 201412:55 pmRNSCorrection: Director's Dealing
28th Nov 201410:35 amRNSDirector's Dealing
28th Nov 20147:00 amRNSDirector's Dealing
26th Nov 20147:00 amRNSHalf Yearly Report
24th Oct 20147:00 amRNSTrading Update and Notice of Interim Results
28th Aug 201412:39 pmRNSResult of AGM
1st Jul 20147:00 amRNSmHealth partnership in Sub-Saharan Africa
23rd Jun 20147:00 amRNSFinal Results
14th Apr 20147:00 amRNSTrading Update and Notice of Results
24th Mar 20144:34 pmRNSDirector/PDMR Shareholding
5th Mar 20142:38 pmRNSDirector/PDMR Shareholding
4th Mar 20143:07 pmRNSHolding(s) in Company
3rd Mar 201411:30 amRNSHolding(s) in Company
28th Feb 201412:42 pmRNSHolding(s) in Company
25th Feb 201411:38 amRNSGrant of Options
25th Feb 201410:06 amRNSCD4 - Grant of ARIPO Patent
24th Feb 20147:00 amRNSCD4 - UNITAID Grant Funding
24th Feb 20147:00 amRNSAllergy Development Update
21st Feb 20142:55 pmRNSHolding(s) in Company
13th Feb 20147:00 amRNSSuccessful completion of CD4 Technology Transfer
20th Dec 20137:00 amRNSCD4 Update
17th Dec 201310:27 amRNSHolding(s) in Company
27th Nov 20137:00 amRNSInterim Results
31st Oct 20137:00 amRNSCD4 Update
17th Oct 20137:00 amRNSTrading Update and Notice of Interim Results
26th Sep 20137:00 amRNSCD4 Update
28th Aug 201311:59 amRNSResult of AGM
17th Jul 201312:10 pmRNSHolding(s) in Company
15th Jul 201311:58 amRNSDirector/PDMR Shareholding
4th Jul 201311:22 amRNSGrant of Options
3rd Jul 20132:21 pmRNSHolding(s) in Company
1st Jul 20137:00 amRNSFinal Results
21st Jun 20137:00 amRNSAllergy Development Update
17th Jun 201310:03 amRNSHolding(s) in Company
10th Jun 201312:18 pmRNSResult of GM
24th May 20137:00 amRNSFundraising to raise £4 million
23rd Apr 20137:00 amRNSGrant of US Patent
22nd Apr 20137:00 amRNSDirectorate Change
10th Apr 20137:00 amRNSDistribution Agreement
10th Apr 20137:00 amRNSTrading Update and Notice of Results
4th Mar 20137:00 amRNSChange of Adviser
17th Dec 20127:00 amRNSChina approves Registration of Food Detective
13th Dec 20127:00 amRNSBanking Facilities increased
3rd Dec 20124:17 pmRNSHolding(s) in Company
21st Nov 20127:00 amRNSHalf Yearly Report
19th Nov 20127:00 amRNSGrant funding award
15th Oct 20127:00 amRNSAgreement with Super Religare Laboratories
15th Oct 20127:00 amRNSTrading Update & Notice of Results
28th Aug 201211:49 amRNSResult of AGM
23rd Jul 20127:00 amRNSPublication of Annual Report and Notice of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.